Reversible parkinsonism and cognitive impairment with chronic valproate use.
Following our initial report of the insidious development of reversible, valproate-induced hearing, motor, and cognitive dysfunction in two patients, we evaluated 36 patients in an epilepsy clinic who had been taking therapeutic levels of valproate for at least 12 months; 29 of these patients were examined according to a prospective protocol. We observed varying degrees of parkinsonism and cognitive impairment, from none to severe. Discontinuation of valproate in 32 affected patients led to subjective and objective improvement on follow-up testing at least 3 months later. Improvement was greatest in patients who were affected most. We conclude that a syndrome of reversible parkinsonism and cognitive impairment may develop insidiously in patients who have been treated with valproate for more than 12 months. The association with valproate may be overlooked due to the insidious onset.
Armon
C
C
Department of Neurology, Loma Linda University Medical School, Loma Linda, CA 92357, USA.
Shin
C
C
Miller
P
P
Carwile
S
S
Brown
E
E
Edinger
J D
JD
Paul
R G
RG
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D003072:Cognition Disorders / Q000139:chemically induced*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000523:psychology; D011581:Psychological Tests; D014635:Valproic Acid / Q000009:adverse effects* / Q000627:therapeutic use*
D014635:Valproic Acid